v3.26.1
Condensed Balance Sheets - USD ($)
Jun. 30, 2026
Dec. 31, 2025
Dec. 31, 2024
Liabilities, Current [Abstract]      
Accrued expenses $ 225 $ 659  
TOTAL LIABILITIES 138,062,603 659  
Commitments and Contingencies  
SHAREHOLDERS' DEFICIT      
Additional paid-in capital 10 10  
Accumulated deficit (138,062,603) (659)  
Total Stockholder's Deficit (138,062,603) (659)  
Archimedes Tech SPAC Partners II Co      
Assets, Current [Abstract]      
Cash 414,970 1,362,766  
Prepaid Expense, Current 100,521 111,403  
Total current assets 515,491 1,474,169  
Deferred offering costs     $ 429,691
Prepaid insurance   9,896  
Demand deposit held in Trust Account 244,162,068 239,860,969 0
TOTAL ASSETS 244,677,559 241,345,034 429,691
Liabilities, Current [Abstract]      
Accrued expenses 576,160 61,277 23,000
Accrued offering costs   75,000 268,358
Accounts Payable, Current   1,239 0
Total current liabilities 138,518,160 137,516 483,391
Deferred underwriting fee payable 8,050,000 8,050,000  
TOTAL LIABILITIES 146,568,160 8,187,516 483,391
Commitments and Contingencies  
Ordinary shares subject to possible redemption, 23,000,000 shares at redemption value of $10.62 and $10.43 per share as of June 30, 2026 and December 31, 2025, respectively 244,162,068 239,860,969  
SHAREHOLDERS' DEFICIT      
Preferred Stock, Value, Issued  
Ordinary shares, $0.0001 par value; 400,000,000 shares authorized; 6,590,000 shares issued and outstanding (excluding 23,000,000 shares subject to possible redemption) as of March 31, 2026 and December 31, 2025 659 659 575
Additional paid-in capital     24,425
Accumulated deficit (146,053,328) (6,704,110) (78,700)
Total Stockholder's Deficit (146,052,669) (6,703,451) (53,700)
TOTAL LIABILITIES AND STOCKHOLDER'S DEFICIT 244,677,559 241,345,034 [1] 429,691 [1]
Related Party [Member] | Archimedes Tech SPAC Partners II Co      
Liabilities, Current [Abstract]      
Accounts Payable, Current $ 0 $ 1,239  
Promissory note - related party     $ 192,033
[1] As of December 31, 2024, included an aggregate of up to 750,000 ordinary shares that were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option was exercised (see Note 5). On February 12, 2025, the Company consummated its Initial Public Offering and sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional units to cover the over-allotment; as a result, the 750,000 ordinary shares were no longer subject to forfeiture.